

## AMENDMENT

This listing of claims will replace all prior versions and listings of claims in the application.

### Listing of claims:

Claim 1 (currently amended): A conformationally restricted polyamine analog of the formula:



wherein each A is independently selected from the group consisting of: a single bond, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>2</sub>-C<sub>6</sub> alkenyl;


each B is independently selected from the group consisting of: ~~a single bond~~, C<sub>1</sub>-C<sub>6</sub> alkyl [,], and C<sub>2</sub>-C<sub>6</sub> alkenyl;


and each E is independently selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>3</sub>-C<sub>6</sub> cycloaryl, and C<sub>3</sub>-C<sub>6</sub> cycloalkenyl;

with the proviso that at least one A moiety is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub> alkenyl;

and any salt or stereoisomer thereof.


Claim 2 (original): A conformationally restricted polyamine analog according to claim 1, selected from the group consisting of





stereoisomer thereof.

Claim 3 (currently amended): A conformationally restricted polyamine analog of the formula:



wherein each A is independently selected from the group consisting of: a single bond, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>2</sub>-C<sub>6</sub> alkenyl;


each B is independently selected from the group consisting of: ~~a single bond~~, C<sub>1</sub>-C<sub>6</sub> alkyl [[,]] and C<sub>2</sub>-C<sub>6</sub> alkenyl;

each E is independently selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>3</sub>-C<sub>6</sub> cycloaryl, and C<sub>3</sub>-C<sub>6</sub> cycloalkenyl; and x is an integer from 2 to 16;


with the proviso that at least one A moiety is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub> alkenyl;

and any salt or stereoisomer thereof.

Claim 4 (original): A conformationally restricted polyamine analog according to claim 3, selected from the group consisting of:



and



;

and any salt or stereoisomer thereof.

Claim 5 (currently amended): A polyamine analog of the formula:

$E-NH-B-A-B-NH-B-A-B-NH-B-A-B-NH(-B-A-B-NH)_x-E$

wherein each A is independently selected from the group consisting of: a single bond and C<sub>2</sub>-C<sub>6</sub> alkenyl;

each B is independently selected from the group consisting of: ~~a single bond~~, C<sub>1</sub>-C<sub>6</sub> alkyl [,], and C<sub>2</sub>-C<sub>6</sub> alkenyl;


each E is independently selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkanol, C<sub>3</sub>-C<sub>6</sub> cycloalkanol, and C<sub>3</sub>-C<sub>6</sub> hydroxyaryl,



with the proviso that at least one E moiety be selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkanol, C<sub>3</sub>-C<sub>6</sub> cycloalkanol, and C<sub>3</sub>-C<sub>6</sub> hydroxyaryl;

and x is an integer from 0 to 16;

and any salt or stereoisomer thereof.

Claim 6 (original): A polyamine analog according to claim 5, selected from the group consisting of:





and all salts and stereoisomers thereof.

Claims 7-15 (canceled)

Claim 16 (original): ~~The polyamine analog~~ A compound of claim 1, further comprising a pharmaceutically acceptable excipient.

Claim 17 (currently amended): A method of treating ~~an indication~~ cancer in an individual comprising the step of administering to the individual a therapeutic amount of a ~~polyamine analog~~ compound of claim ~~1~~ 3.

Claim 18 (original): The method of claim 17, wherein the individual is a human.

Claim 19 (canceled)

Claim 20 (currently amended): The method of claim ~~19~~ 17, wherein the cancer affects cells of the bladder, blood, brain, breast, colon, digestive tract, lung, ovaries, pancreas, prostate gland, or skin.

Claim 21 (currently amended) ~~The method of claim 17, wherein the indication is~~ A method of treating a disease in an individual, wherein the disease is selected from Alzheimer's

disease, epilepsy, ~~multiple sclerosis, problems associated with tissue grafts and organ transplants,~~  
~~psoriasis, restenosis, stomach ulcers, or tissue overgrowth after surgery,~~ or an infection or  
infestation of parasites ~~[[,]] bacteria, or fungi or insects.~~ , comprising administering to the  
individual a therapeutically effective amount of a compound of claim 3.

Claim 22 (currently amended): A method of suppressing cell growth in an individual comprising the step of administering to the individual a therapeutic amount of a ~~polyamine analog compound~~ of claim 1 3.

Claim 23. (original): The method of claim 22, wherein the individual is a human.

Claims 24-31 (canceled)

Claim 32. (currently amended): The method of claim 17, wherein the ~~indication~~  
cancer is breast cancer.

Claim 33 (new): A method of treating cancer in an individual comprising the step of administering to the individual a therapeutic amount of a compound of claim 1.

Claim 34 (new): The method of claim 33, wherein the cancer is breast cancer.

Claim 35 (new): A method of treating cancer in an individual comprising the step of administering to the individual a therapeutic amount of a compound of claim 4.

Claim 36 (new): The method of claim 35, wherein the cancer is breast cancer.

Claim 37 (new): A compound of claim 3, further comprising a pharmaceutically acceptable excipient.

Claim 38 (new): A compound of claim 4, further comprising a pharmaceutically acceptable excipient.